These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31924740)

  • 1.
    Ye S; Hu X; Ni C; Jin W; Xu Y; Chang L; Zhou H; Jiang J; Yang L
    Mol Cancer Ther; 2020 Mar; 19(3):956-965. PubMed ID: 31924740
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
    Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
    [No Abstract]   [Full Text] [Related]  

  • 3. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
    Takegawa N; Yonesaka K; Sakai K; Ueda H; Watanabe S; Nonagase Y; Okuno T; Takeda M; Maenishi O; Tsurutani J; Satoh T; Okamoto I; Nishio K; Tamura T; Nakagawa K
    Oncotarget; 2016 Jan; 7(3):3453-60. PubMed ID: 26657506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients.
    Jing C; Wang T; Ma R; Cao H; Wang Z; Liu S; Chen D; Zhang J; Wu Y; Zhang Y; Wu J; Feng J
    Mol Carcinog; 2020 May; 59(5):478-491. PubMed ID: 32141150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
    Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
    JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
    Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
    Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer.
    Kim SY; Kim K; Cho SH; Chun SM; Tak E; Hong YS; Kim JE; Kim TW
    Cancer Genet; 2021 Nov; 258-259():27-36. PubMed ID: 34315006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
    Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2
    Gharib E; Salmanipour R; Nazemalhosseini Mojarad E; Yaghoob Taleghani M; Sarlak S; Malekzade-Moghani M; Nasrabadi PN; Meiary MA; Asadzadeh Aghdaei H; Zali MR
    J Cell Physiol; 2019 Aug; 234(8):13137-13144. PubMed ID: 30549033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer.
    Peng K; Liu R; Yu Y; Liang L; Yu S; Xu X; Liu T
    Biomed Pharmacother; 2018 Jan; 97():1138-1146. PubMed ID: 29136952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells.
    Park SM; Hwang CY; Cho SH; Lee D; Gong JR; Lee S; Nam S; Cho KH
    FEBS J; 2019 Apr; 286(7):1305-1318. PubMed ID: 30719834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine.
    Valentini AM; Cavalcanti E; Di Maggio M; Caruso ML
    Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):539-544. PubMed ID: 30199395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
    Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.
    Perrone F; Lampis A; Orsenigo M; Di Bartolomeo M; Gevorgyan A; Losa M; Frattini M; Riva C; Andreola S; Bajetta E; Bertario L; Leo E; Pierotti MA; Pilotti S
    Ann Oncol; 2009 Jan; 20(1):84-90. PubMed ID: 18669866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
    Borrero-Palacios A; Cebrián A; Gómez Del Pulgar MT; García-Carbonero R; Garcia-Alfonso P; Aranda E; Elez E; López-López R; Cervantes A; Valladares M; Nadal C; Viéitez JM; Guillén-Ponce C; Rodríguez J; Hernández I; García JL; Vega-Bravo R; Puime-Otin A; Martínez-Useros J; Del Puerto-Nevado L; Rincón R; Rodríguez-Remírez M; Rojo F; García-Foncillas J
    Sci Rep; 2019 Feb; 9(1):2589. PubMed ID: 30796344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
    van Helden EJ; Angus L; Menke-van der Houven van Oordt CW; Heideman DAM; Boon E; van Es SC; Radema SA; van Herpen CML; de Groot DJA; de Vries EGE; Jansen MPHM; Sleijfer S; Verheul HMW
    Mol Oncol; 2019 Nov; 13(11):2361-2374. PubMed ID: 31350822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
    Lin JK; Lin AJ; Lin CC; Lan YT; Yang SH; Li AF; Chang SC
    J Surg Oncol; 2011 Nov; 104(6):661-6. PubMed ID: 21671463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
    Zhang H; Yuan L; Liu L; Yan C; Cheng J; Fu Q; Tong Z; Jiang W; Zheng Y; Zhao P; Zhang G; Fang W
    BMC Cancer; 2020 May; 20(1):416. PubMed ID: 32404198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
    Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
    Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
    Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
    Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.